Allogene Therapeutics, Inc.

ALLO · Nasdaq · United States

Share price · ALLO

$0.70-1.33 (-65.72%) 3M

close as of 2026-11-18 · 24h delayed · vol 10.6M (1.1x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when ALLO's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 18 Nov 2026-6.5%
  2. 17 Nov 2026-7.8%
  3. 10 Nov 2026-12.1%
  4. 6 Nov 2026-4.6%
  5. 2 Nov 2026-7.6%

    Nothing announced by ALLO that day or the session before.

  6. 30 Jul 2026+8.8%
  7. 29 Jul 2026+9.0%
  8. 14 Apr 2026-25.5%
  9. 23 Mar 2026+17.9%
  10. 17 Feb 2026+20.0%

Share of unusual movement by asset

For each asset, the share of ALLO's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
cemacabtagene ansegedleucel
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—1%
Other company news (earnings, financing, releases naming no asset)—16%
Sessions with no dated event—83%

Assets

(2 total)
2Total Assets
0Approved
0Phase 3 / Filed
2Phase 1–2 / Early
2Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Phase 2
CD19Cell therapy
Non-Hodgkin Lymphoma
Large B-Cell Lymphoma
Phase 1
BCMACell therapy
Multiple Myeloma

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
December 2027 (1)
cemacabtagene ansegedleucelPhase 2Large B-cell Lymphoma
Est. primary completion 2027-12 · NCT06500273 · CT.gov ↗
What to watch
2029 (1)
February 2029 (1)
cemacabtagene ansegedleucelPhase 1/2Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia …
Est. primary completion 2029-02 · NCT04416984 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$0$42M$40M+ $264M short-term inv.$50M-$36M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$4.6M$31M$49M+ $294M short-term inv.$43M-$32M operating cash flowreport ↗
2026-Q1—$32M$41M+ $237M short-term inv.$43M-$13M operating cash flowreport ↗
2025-Q3$0$31M$48M+ $214M short-term inv.$41M-$30M operating cash flowreport ↗
2025-Q2$0$40M$63M+ $221M short-term inv.$51M-$39M operating cash flowreport ↗
2025-Q1$0$50M$53M+ $238M short-term inv.$60M-$53M operating cash flowreport ↗
2024-Q3$0$45M$62M+ $240M short-term inv.$66M-$44M operating cash flowreport ↗
2024-Q2$0$50M$181M+ $274M short-term inv.$66M-$64M operating cash flowreport ↗
2024-Q1<$0.1M$52M$61M+ $334M short-term inv.$65M-$56M operating cash flowreport ↗
2023-Q3<$0.1M$46M$80M+ $396M short-term inv.$61M-$56M operating cash flowreport ↗
2023-Q2<$0.1M$62M$165M+ $337M short-term inv.$78M-$62M operating cash flowreport ↗
2023-Q1$0.1M$80M$120M+ $361M short-term inv.$99M-$67M operating cash flowreport ↗
2022-Q3$0.1M$64M$85M+ $478M short-term inv.$83M-$48M operating cash flowreport ↗
2022-Q2$0.1M$57M$106M+ $394M short-term inv.$75M-$43M operating cash flowreport ↗
2022-Q1$0.1M$60M$95M+ $365M short-term inv.$80M-$68M operating cash flowreport ↗
2021-Q3$0.1M$59M$199M+ $293M short-term inv.$78M-$49M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$0$150M$62M+ $199M short-term inv.$48M-$149M operating cash flowreport ↗

Allogene Therapeutics reported revenue of $0M for fiscal 2025, a 100.0% YoY decline from $0.02M, with R&D spend of $150.15M, down 21.9% YoY. Cash and equivalents stood at $61.98M, and the company recorded a net loss of $190.89M, with a quarterly net burn of $190.89M.

The company continued advancing its three lead programs: cema-cel in the ALPHA3 trial for large B-cell lymphoma, ALLO-316 in renal cell carcinoma, and ALLO-329 in autoimmune disease. In August 2025, it discontinued the FCA lymphodepletion arm of ALPHA3 and ended ALLO-647 development following a Grade 5 treatment-related serious adverse event; the trial now proceeds with FC lymphodepletion and observation. Allogene plans to announce MRD clearance data from the ALPHA3 interim futility analysis in April 2026, expects initial proof-of-concept data from the ALLO-329 RESOLUTION trial in June 2026, and anticipates completing ALPHA3 enrollment by the end of 2027. The company is also exploring partnering opportunities for ALLO-316.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY<$0.1M$192M$86M+ $217M short-term inv.$64M-$200M operating cash flowreport ↗
2023-FY$0.1M$243M$93M+ $366M short-term inv.$82M-$238M operating cash flowreport ↗
2022-FY$0.2M$256M$72M+ $455M short-term inv.$83M-$221M operating cash flowreport ↗
2021-FY$38M$220M$184M+ $284M short-term inv.$64M-$185M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 14 sales ($668K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-10-21Parker Geoffrey M. · CHIEF FINANCIAL OFFICEROpen-market sale36,342$1.34$49KForm 4
2026-08-21Douglas Earl Martin · SVP, General CounselOpen-market sale29,697$2.12$63KForm 4
2026-07-01Roberts Zachary · President and CEOAward / grant (derivative)134,530——Form 4
2026-07-01Roberts Zachary · President and CEOAward / grant (derivative)476,190——Form 4
2026-06-18Barrett Elizabeth A. · directorAward / grant (derivative)95,400——Form 4
2026-06-18Humer Franz B · directorAward / grant (derivative)95,400——Form 4
2026-06-18WITTE OWEN N. · directorAward / grant (derivative)95,400——Form 4
2026-06-18SATO VICKI L · directorAward / grant (derivative)95,400——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 208 reporting institutions held 184.2M shares ($429.1M, 53.4% of shares outstanding).

#InstitutionSharesValue
1Pfizer Inc22,032,040$49.8M
2BlackRock, Inc.19,091,095$46.6M
3TPG GP A, LLC18,716,306$45.7M
4STATE STREET CORP8,660,306$21.1M
5PRIMECAP MANAGEMENT CO/CA/8,379,840$20.4M
6VANGUARD CAPITAL MANAGEMENT LLC6,921,350$16.9M
7CITADEL ADVISORS LLC6,793,620$16.6M
8TWO SIGMA INVESTMENTS, LP5,375,456$13.1M
9GEODE CAPITAL MANAGEMENT, LLC4,124,178$10.1M
10Frazier Life Sciences Management, L.P.3,796,668$9.3M
11Woodline Partners LP3,501,078$8.5M
12Patient Square Capital LP3,450,000$8.4M
13MARSHALL WACE, LLP3,447,984$8.4M
14MILLENNIUM MANAGEMENT LLC3,322,053$8.1M
15Candriam S.C.A.2,997,318$7.3M